Vancomycin Dosing Adjustment for Multilobar Necrotizing Pneumonia

Introduction to Vancomycin Adjustment

For a patient with multilobar necrotizing pneumonia and vancomycin serum levels of 10.30 mg/L receiving 1 gram every 12 hours, the dose should be increased to 1 gram every 8 hours to achieve adequate therapeutic levels of 15-20 mg/L, as recommended by the Infectious Diseases Society of America 1, 2

Multilobar necrotizing pneumonia is considered a severe infection that requires vancomycin trough levels between 15-20 μg/mL to optimize therapeutic efficacy, according to the Infectious Diseases Society of America 2
The current serum level of 10.30 mg/L is below the recommended therapeutic range for severe infections like multilobar necrotizing pneumonia, as stated by the Infectious Diseases Society of America 1
For severe MRSA infections, guidelines recommend maintaining vancomycin trough concentrations of 15-20 μg/mL to maximize efficacy and prevent resistance, as recommended by the Infectious Diseases Society of America 3, 4

Measure new trough levels before the fourth or fifth dose after adjustment (in steady-state conditions), as recommended by the Infectious Diseases Society of America 1
Obtain trough levels just before administering the next dose, as recommended by the Infectious Diseases Society of America 1, 2

The pharmacodynamic parameter that best predicts vancomycin efficacy is the AUC/MIC ratio, with a target of >400, as recommended by the Infectious Diseases Society of America 2
Trough levels of 15-20 μg/mL correlate best with an AUC/MIC >400 for severe infections, as recommended by the Infectious Diseases Society of America 2

Sustained trough levels >20 μg/mL increase the risk of nephrotoxicity, as warned by the Infectious Diseases Society of America 5
If levels exceed 20 μg/mL after adjustment, consider withholding a dose and then reducing the dose or extending the interval, as recommended by the Infectious Diseases Society of America 5
For patients with multilobar necrotizing pneumonia, some experts consider the use of protein synthesis inhibitors (such as linezolid or clindamycin) as adjunctive therapy, as recommended by the Infectious Diseases Society of America 3, 6